Clinical Approaches to Minimize Rash Associated With EGFR Inhibitors

Karen Oishi, APRN, MSN, GNP-C, ANP-C, OCN®

**Key Points . . .**

- The clinical use of epidermal growth factor receptor (EGFR) inhibitors will continue to grow as more indications are approved, additional agents enter clinical trials, and new combinations of agents are studied.
- One of the most common adverse events associated with EGFR inhibitors is a skin rash that, although usually mild to moderate in severity, can negatively affect patients’ quality of life and interfere with cancer treatment.
- The grading of rash can be subjective. Clinicians and patients should collaborate to determine how to treat rashes.
- Although no evidence-based treatment guidelines have been established for the treatment of the skin rash, this adverse event is manageable using the approach outlined in this article.

Clinical oncology recently has shifted from the use of traditional cytotoxic chemotherapeutic agents that target rapidly dividing cells to the use of therapies that target proteins implicated in the development and progression of cancer. These proteins include Bcr-Abl fusion protein found in patients with chronic myelogenous leukemia, the vascular endothelial growth factor involved in the development of several solid tumors, and the epidermal growth factor receptor (EGFR) implicated in the development and progression of many different cancers. In contrast to chemotherapeutic agents, which can cause anemia, neutropenia, severe nausea and vomiting, neuropathy, and total alopecia, targeted therapies generally are well tolerated and have less severe systemic adverse events (Herbst & Bunn, 2003; Silvestri & Rivera, 2005).

Targeted agents are not, however, without adverse events. Agents targeted against EGFR have a distinct toxicity profile that includes diarrhea and various cutaneous toxicities, the most common of which is a rash that often is accompanied by dryness and pruritus. Although usually mild to moderate in severity, skin rash can have a significant negative effect on patients’ quality of life. In addition to dryness and itching, which can be very uncomfortable, people often are self-conscious about the rash, which is frequently in highly visible areas such as the face, neck, and chest.

This article will focus on effective management of EGFR inhibitor–related adverse events, specifically rash, with an emphasis on maintaining patients’ quality of life during treatment and limiting the effect of rash on the course of cancer treatment so that patients remain on it for as long as necessary.

**EGFR as a Target for Cancer Therapy**

EGFR, also known as human epidermal receptor (HER) 1, is a member of the HER family of receptor tyrosine kinases, which also includes HER2, HER3, and HER4 receptors (Yarden, 2001). After binding their respective ligands (extracellular proteins that specifically bind to them), the receptors pair with each other as homodimers (e.g., EGFR-EGFR) or heterodimers (e.g., EGFR-HER2) and initiate a cascade of signals that direct a cell’s growth, proliferation, response to other signals, and ability to move within tissue (Yarden & Sliwkowski, 2001). Consequently, the HER family receptor tyrosine kinases play important roles in the regulation of growth and differentiation in normal and neoplastic...